EP1966189A1 - Heterocycles bicycliques, medicaments contenant ces composes, utilisation et procede de fabrication de ceux-ci - Google Patents

Heterocycles bicycliques, medicaments contenant ces composes, utilisation et procede de fabrication de ceux-ci

Info

Publication number
EP1966189A1
EP1966189A1 EP06819573A EP06819573A EP1966189A1 EP 1966189 A1 EP1966189 A1 EP 1966189A1 EP 06819573 A EP06819573 A EP 06819573A EP 06819573 A EP06819573 A EP 06819573A EP 1966189 A1 EP1966189 A1 EP 1966189A1
Authority
EP
European Patent Office
Prior art keywords
cyclohex
cis
trans
amino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06819573A
Other languages
German (de)
English (en)
Inventor
Frank Himmelsbach
Marco Santagostino
Birgit Jung
Rainer Soyka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim International GmbH
Priority to EP06819573A priority Critical patent/EP1966189A1/fr
Publication of EP1966189A1 publication Critical patent/EP1966189A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Definitions

  • Bicyclic heterocycles medicaments containing these compounds, their use and processes for their preparation
  • the present invention relates to bicyclic heterocycles of the general formula
  • R a is a hydrogen atom
  • R b is a 3-chloro-4-fluoro-phenyl group or 3-ethynylphenyl group
  • R c is a radical selected from the group consisting of 1-methoxycarbonyl-piperidin-4-yl, i-ethyloxycarbonyl-piperidin-4-yl, 1-trifluoroacetyl-piperidin-4-yl, cis-4
  • R d is a hydrogen atom or a methoxy, ethyloxy or 2-methoxyethyloxy group, preferably a methoxy or ethyloxy group,
  • the compounds of the general formula (I) can be prepared, for example, by the following processes:
  • R a , R b and R d are as defined above, with a compound of the general formula
  • R c is defined as mentioned above and Z 1 represents a leaving group such as a halogen atom, for example a chlorine or bromine atom, a sulphonyloxy group such as a methanesulfonyloxy or p-toluenesulfonyloxy group or a hydroxy group.
  • Z 1 represents a leaving group such as a halogen atom, for example a chlorine or bromine atom, a sulphonyloxy group such as a methanesulfonyloxy or p-toluenesulfonyloxy group or a hydroxy group.
  • reaction is conveniently carried out in a solvent such as ethanol, isopropanol, acetonitrile, toluene, tetrahydrofuran, dioxane, dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidinone, optionally in the presence of a base such as potassium carbonate or N-ethyl-diisopropylamine, at temperatures in the range of 20 0 C to 160 0 C, preferably at temperatures in the range of 80 ° C to 140 0 C.
  • a solvent such as ethanol, isopropanol, acetonitrile, toluene, tetrahydrofuran, dioxane, dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidinone
  • a base such as potassium carbonate or N-ethyl-diisopropylamine
  • a halogenating agent for example an acid halide such as thionyl chloride, thionyl bromide, phosphorus trichloride, phosphorus pentachloride or phosphorus oxychloride to form an intermediate compound of the general formula (V),
  • a halogenating agent for example an acid halide such as thionyl chloride, thionyl bromide, phosphorus trichloride, phosphorus pentachloride or phosphorus oxychloride
  • R c and R are defined as mentioned above and Z represents a halogen atom, such as a chlorine or bromine atom,
  • R a and R b are defined as mentioned above.
  • the reaction with the halogenating agent is optionally carried out in a solvent such as methylene chloride, chloroform, acetonitrile or toluene and optionally in the presence of a base such as N, N-diethylaniline or N-ethyl-diisopropylamine at temperatures in the range of 20 0 C to 160 0 C, preferably carried out from 40 ° C to 120 0 C.
  • the reaction is carried out with thionyl chloride and catalytic amounts of dimethylformamide at the boiling temperature of the reaction mixture.
  • the Reaction with phosphorus oxychloride in the presence of triethylamine with acetonitrile as solvent at the boiling point of the reaction mixture.
  • reaction of the compound of the general formula (V) with a compound of the general formula (VI) is conveniently carried out in a solvent such as ethanol, isopropanol, acetonitrile, dioxane or dimethylformamide, optionally in the presence of a base such as potassium carbonate or N-ethyl-diisopropylamine Temperatures in the range of 20 0 C and 160 0 C, preferably from 60 ° C to 120 0 C. Preferably, however, the reaction is carried out in isopropanol at the boiling point of the reaction mixture.
  • a solvent such as ethanol, isopropanol, acetonitrile, dioxane or dimethylformamide
  • a base such as potassium carbonate or N-ethyl-diisopropylamine
  • a further preferred variant consists of further reacting the solution of general formula (V) obtained after reaction with phosphorus oxychloride in the presence of triethylamine with acetonitrile as solvent with a solution of the compound of general formula (VI), preferably at a temperature between 20-80 ° C.
  • R c for the preparation of compounds of the general formula (I) in which R c is a 1-methoxycarbonyl-piperidin-4-yl, 1-ethyloxycarbonyl-piperidin-4-yl, 1-trifluoroacetyl-piperidin-4-yl , cis -4- (methoxycarbonylamino) -cyclohex-1-yl, trans-4-
  • R a , R b and R d are defined as mentioned above, and R c is a piperidin-4-yl, cis-4-amino-cyclohex-1-yl, trans-4-amino-cyclohex-1 - represents yl, cis-4- (methylamino) -cyclohex-1-yl or trans-4- (methylamino) -cyclohex-1-yl group,
  • acylating agent such as methyl chloroformate, ethyl chloroformate, pyrocarbonic acid dimethyl ester, Pyrokohlenklathyl ester, trifluoroacetic anhydride or methyl trifluoroacetate.
  • the reaction is conveniently carried out in a solvent such as methylene chloride, acetonitrile, toluene, tetrahydrofuran, dioxane, dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidinone, preferably in tetrahydrofuran or dioxane, optionally in the presence of a base such as potassium carbonate, sodium hydroxide or N-ethyl-diisopropylamine, at temperatures in the range from -20 0 C to 80 0 C, preferably from 0 0 C to 40 0 C.
  • a base such as potassium carbonate, sodium hydroxide or N-ethyl-diisopropylamine
  • R a , R b and R d are defined as mentioned above, and R c represents a cis-4-aminocyclohex-1-yl or trans-4-amino-cyclohex-i-yl group,
  • phthalic anhydride or another reactive derivative of phthalic acid.
  • the reaction is conveniently carried out in a solvent such as acetic acid, acetonitrile, toluene, tetrahydrofuran, dioxane, dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidinone, optionally in the presence of a base such as potassium carbonate or N-ethyl-diisopropylamine, in a temperature range of 60 0 C to 160 0 C, preferably from 80 ° C to 120 0 C.
  • a solvent such as acetic acid, acetonitrile, toluene, tetrahydrofuran, dioxane, dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidinone
  • a base such as potassium carbonate or N-ethyl-diisopropylamine
  • the reaction is carried out in acetic acid at temperatures between 80 ° C to 120 ° C.
  • R a , R b , R c and R d are as defined above.
  • the obtained compounds of the general formula (I) can be separated into their diastereomers.
  • cis / trans mixtures can be separated into their cis and trans isomers, for example by chromatography.
  • the compounds of the formula (I) obtained can be converted into their salts, in particular for the pharmaceutical application, into their physiologically tolerated salts with inorganic or organic acids.
  • acids for this example, hydrochloric acid, Hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid into consideration.
  • the compounds of the general formula (I) according to the invention and their physiologically tolerable salts have valuable pharmacological properties, in particular an inhibitory effect on the signal transduction mediated by the epidermal growth factor receptor (EGF-R), which is inhibited, for example, by inhibition of ligand binding Receptor dimerization or the tyrosine kinase itself can be effected.
  • EGF-R epidermal growth factor receptor
  • the inhibition of the human EGF receptor kinase was determined with the aid of the cytoplasmic tyrosine kinase domain (methionine 664 to alanine 1186 based on the sequence published in Nature 309 (1984), 418).
  • the protein was expressed in Sf9 insect cells as a GST fusion protein using the baculovirus expression system.
  • the measurement of enzyme activity was carried out in the presence or absence of the test compounds in serial dilutions.
  • the polymer pEY (4: 1) from SIGMA was used as a substrate.
  • Biotinylated pEY (bio-pEY) was added as a tracer substrate.
  • Each 100 ⁇ l reaction solution contained 10 ⁇ l of the inhibitor in 50% DMSO, 20 ⁇ l of the substrate solution (200 mM HEPES pH 7.4, 50 mM magnesium acetate, 2.5 mg / ml poly (EY), 5 ⁇ g / ml bio-pEY) and 20 ⁇ l enzyme preparation.
  • the enzyme reaction was started by adding 50 ⁇ l of a 100 ⁇ M ATP solution in 10 mM magnesium chloride.
  • the dilution of the Enzyme preparation was adjusted so that the phosphate incorporation into the bio-pEY was linear in terms of time and amount of enzyme.
  • the enzyme preparation was diluted in 20 mM HEPES pH 7.4, 1 mM EDTA, 130 mM saline, 0.05% Triton X-100, 1 mM DTT and 10% glycerol.
  • the enzyme assays were performed at room temperature for a period of 30 minutes and terminated by addition of 50 ⁇ l of a stop solution (250 mM EDTA in 20 mM HEPES pH 7.4). 100 ⁇ l was placed on a streptavidin-coated microtiter plate and incubated for 60 minutes at room temperature. Thereafter, the plate was washed with 200 ⁇ l of a washing solution (50 mM Tris, 0.05% Tween 20). After addition of 100 ⁇ l of an HRPO-labeled anti-PY antibody (PY20H anti-PTyr: HRP from Transduction Laboratories, 250 ng / ml) was incubated for 60 minutes.
  • a stop solution 250 mM EDTA in 20 mM HEPES pH 7.4
  • 100 ⁇ l was placed on a streptavidin-coated microtiter plate and incubated for 60 minutes at room temperature. Thereafter, the plate was washed with 200 ⁇ l of a washing solution (
  • microtiter plate was washed three times with 200 ul of washing solution.
  • Correlation coefficients of above 0.9 and the upper and lower values of the curves showed a spread of at least a factor of 5. From the curves, the drug concentration was derived, which inhibits the activity of the EGF receptor kinase to 50% (IC50).
  • the compounds according to the invention have IC 50 values of less than 100 ⁇ M.
  • the compounds of the general formula I according to the invention thus inhibit the signal transduction by tyrosine kinases, as shown by the example of the human EGF receptor, and are therefore useful for the treatment of pathophysiological processes which are caused by hyperfunction of tyrosine kinases.
  • pathophysiological processes which are caused by hyperfunction of tyrosine kinases.
  • tyrosine kinases are, for example, benign or malignant tumors, in particular Tumors of epithelial and neuroepithelial origin, metastasis and abnormal proliferation of vascular endothelial cells (neoangiogenesis).
  • the compounds of the invention are also useful for the prevention and treatment of respiratory and pulmonary diseases associated with increased or altered mucus production caused by stimulation of tyrosine kinases, e.g. in inflammatory diseases
  • Respiratory tracts such as acute bronchitis, chronic bronchitis, chronic obstructive
  • COPD Bronchitis
  • asthma bronchiectasis
  • allergic or non-allergic rhinitis or sinusitis rhinitis or sinusitis
  • cystic fibrosis ⁇ 1-antitrypsin deficiency, or cough
  • Pulmonary emphysema, pulmonary fibrosis and hyperreactive airways Pulmonary emphysema, pulmonary fibrosis and hyperreactive airways.
  • the compounds are also useful in the treatment of inflammatory diseases of the gastrointestinal tract and the bile ducts and bladder associated with impaired activity of the tyrosine kinases, e.g. in acute or chronic inflammatory changes, such as cholecystitis, Crohn's disease, ulcerative colitis, and ulcers or polyposis in the gastrointestinal tract or as they occur in diseases of the gastrointestinal tract, which are associated with increased secretion such as M. Menetrier, secreting adenomas and protein loss syndromes,
  • inflammatory diseases of the joints such as rheumatoid arthritis
  • inflammatory diseases of the skin, eyes in inflammatory pseudopolyps, in colitis cystica profunda or in pneumatosis cystoides intestinales.
  • the compounds are also contemplated for the treatment of CNS and spinal cord injuries.
  • Preferred areas of application include inflammatory diseases of the respiratory organs or of the intestine, such as chronic bronchitis (COPD), chronic sinusitis, asthma, Crohn's disease, ulcerative colitis or polyposis of the intestine.
  • COPD chronic bronchitis
  • chronic sinusitis asthma, Crohn's disease, ulcerative colitis or polyposis of the intestine.
  • Particularly preferred indications are inflammatory diseases of the respiratory tract or the lungs, such as chronic bronchitis (COPD) or asthma.
  • COPD chronic bronchitis
  • the compounds of general formula (I) and their physiologically acceptable salts can be used for the treatment of other diseases caused by aberrant function of tyrosine kinases, such as epidermal hyperproliferation (psoriasis), benign prostate hyperplasia (BPH), inflammatory processes, diseases of the Immune system, hyperproliferation of hematopoietic cells, the treatment of nasal polyps, etc ..
  • the compounds of the invention can be used alone or in combination with other pharmacologically active compounds, for example in tumor therapy in monotherapy or in combination with other anti-tumor therapeutics, for example in combination with topoisomerase inhibitors (eg etoposide), mitotic inhibitors (eg, vinblastine), nucleic acid-interacting compounds (eg, cisplatin, cyclophosphamide, adriamycin), hormone antagonists (eg, tamoxifen), inhibitors of metabolic processes (eg, 5-FU, etc.), cytokines (eg, interferons), antibodies, etc.
  • topoisomerase inhibitors eg etoposide
  • mitotic inhibitors eg, vinblastine
  • nucleic acid-interacting compounds eg, cisplatin, cyclophosphamide, adriamycin
  • hormone antagonists eg, tamoxifen
  • inhibitors of metabolic processes eg, 5-FU, etc.
  • these compounds alone or in combination with other respiratory therapies, such as secretolytically (e.g., ambroxol, N-acetylcysteine), broncholytic (e.g., tiotropium or ipratropium or fenoterol, salmeterol, salbutamol) and / or anti-inflammatory (e.g., theophylline or
  • Glucocorticoids are used for the treatment of diseases in the region of the gastrointestinal tract. These compounds can also be given alone or in combination with motility or secretion-influencing substances. These combinations can be administered either simultaneously or sequentially.
  • the use of these compounds may be intravenous, subcutaneous, intramuscular, intraperitoneal, intranasal, by inhalation or transdermally or orally, in particular aerosol formulations being suitable for inhalation.
  • the compounds according to the invention are generally used in warm-blooded vertebrates, in particular in humans, in dosages of 0.001-100 mg / kg body weight, preferably at 0.1-15 mg / kg.
  • these are with one or more conventional inert carriers and / or diluents, for example with corn starch, lactose, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerol, water / sorbitol, water / Polyethylene glycol, propylene glycol, stearyl alcohol, carboxymethyl cellulose or fatty substances such as hard fat or their suitable mixtures in common pharmaceutical preparations such as tablets, dragees, capsules, powders, suspensions, solutions, sprays or suppositories incorporated.
  • corn starch, lactose cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerol, water / sorbitol, water / Polyethylene glycol, propylene glycol,
  • the compounds of the general formula (I) according to the invention are also suitable for the preparation of derivatives, as described, for example, in WO 03/082290.
  • the compound of Example 1 can be reacted with sodium hydroxide solution or potassium hydroxide solution to give 4 - [(3-chloro-4-fluorophenyl) amino] -6- (piperidin-4-yloxy) -7-methoxyquinazoline (see Process Example A ).
  • 1 drag core contains:
  • the active substance is treated with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and half of the specified amount of magnesium Stearate mixed.
  • a tableting machine compacts are produced with a diameter of about 13 mm, these are ground on a suitable machine through a sieve with 1.5 mm mesh size and mixed with the remaining amount of magnesium stearate. This granulate is pressed on a tabletting machine into tablets of the desired shape.
  • coated dragee cores are coated with a film consisting essentially of hydroxypropylmethylcellulose.
  • the finished film dragees are shined with beeswax.
  • Composition 1 tablet contains:
  • Tablet weight 220 mg Diameter: 10 mm, biplan with facet on both sides and one-sided part notch.
  • Composition 1 tablet contains: active substance 150.0 mg lactose powdered 89.0 mg cornstarch 40.0 mg
  • the active substance mixed with milk sugar, corn starch and silica is moistened with a 20% strength aqueous solution of polyvinylpyrrolidone and beaten through a sieve with a mesh size of 1.5 mm.
  • the granules dried at 45 ° C are again rubbed through the same sieve and mixed with the stated amount of magnesium stearate. From the mixture tablets are pressed.
  • Composition 1 capsule contains:
  • the active ingredient is mixed with the excipients, passed through a sieve of 0.75 mm mesh size and mixed homogeneously in a suitable device.
  • the final mixture is filled into size 1 hard gelatin capsules.
  • Capsule filling approx. 320 mg capsule shell: hard gelatine capsule size 1.
  • Composition 1 suppository contains:
  • Polyethylene glycol 1500 550.0 mg
  • the active ingredient is distributed homogeneously therein and the melt is poured into pre-cooled molds.
  • Carboxymethylcellulose Na salt 0.10 g p-hydroxybenzoic acid methyl ester 0.05 g p-hydroxybenzoic acid propyl ester 0.01 g
  • Distilled water is heated to 70 0 C.
  • p-hydroxybenzoic acid methyl ester and propyl ester and glycerol and carboxymethyl cellulose sodium salt are dissolved with stirring. It is cooled to room temperature and added with stirring, the active ingredient and dispersed homogeneously. After addition and dissolution of the sugar, the sorbitol solution and the aroma, the suspension is evacuated to vent with stirring.
  • 5 ml of suspension contain 50 mg of active ingredient.
  • the active ingredient is dissolved in the required amount of 0.01 N HCl, isotonic with saline, sterile filtered and filled into 2 ml ampoules.
  • Active ingredient 50.0 mg 0.01 n hydrochloric acid s.g.
  • the active ingredient is dissolved in the required amount 0.01 N HCl, made isotonic with sodium chloride, sterile filtered and filled into 10 ml ampoules.
  • 1 capsule contains:
  • the active substance is mixed with lactose for inhalation purposes.
  • the mixture is filled into capsules on a capsule machine (weight of the empty capsule approx. 50 mg).
  • 1 hub contains:
  • the active substance and benzalkonium chloride are dissolved in ethanol / water (50/50).
  • the pH of the solution is adjusted with 1 N hydrochloric acid.
  • the adjusted solution is filtered and filled into containers suitable for the hand nebulizer (cartridges).
  • the title compound can be prepared from 4-chloro-6- (1-methylsulfonyl-piperidin-4-yloxy) -7-ethoxy-quinazoline hydrochloride (Example VII (25)) by reaction with 3-chloro-4-fluoroaniline in isopropanol at reflux temperature. The work-up is carried out as described in Example 1.

Abstract

L'invention concerne des hétérocycles bicycliques représentés par la formule (I), leurs tautomères, stéréoisomères, mélanges et sels, notamment leurs sels physiologiquement compatibles, contenant des acides anorganiques ou organiques, présentant des propriétés pharmaceutiques intéressantes, notamment un effet inhibiteur sur la transduction de signal provoquée par des tyrosine kinases. L'invention concerne également l'utilisation de ces composés pour le traitement de maladies, notamment de maladies tumorales, de l'hyperplasie prostatique bénigne (BPH), de maladies pulmonaires et de maladies des voies respiratoires, ainsi que leur fabrication.
EP06819573A 2005-12-12 2006-11-17 Heterocycles bicycliques, medicaments contenant ces composes, utilisation et procede de fabrication de ceux-ci Withdrawn EP1966189A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06819573A EP1966189A1 (fr) 2005-12-12 2006-11-17 Heterocycles bicycliques, medicaments contenant ces composes, utilisation et procede de fabrication de ceux-ci

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05111955 2005-12-12
EP06118305 2006-08-02
PCT/EP2006/068598 WO2007068552A1 (fr) 2005-12-12 2006-11-17 Heterocycles bicycliques, medicaments contenant ces composes, utilisation et procede de fabrication de ceux-ci
EP06819573A EP1966189A1 (fr) 2005-12-12 2006-11-17 Heterocycles bicycliques, medicaments contenant ces composes, utilisation et procede de fabrication de ceux-ci

Publications (1)

Publication Number Publication Date
EP1966189A1 true EP1966189A1 (fr) 2008-09-10

Family

ID=37734070

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06819573A Withdrawn EP1966189A1 (fr) 2005-12-12 2006-11-17 Heterocycles bicycliques, medicaments contenant ces composes, utilisation et procede de fabrication de ceux-ci

Country Status (11)

Country Link
US (1) US20070135463A1 (fr)
EP (1) EP1966189A1 (fr)
JP (1) JP2009518450A (fr)
KR (1) KR20080077009A (fr)
AR (1) AR058286A1 (fr)
AU (1) AU2006326157A1 (fr)
BR (1) BRPI0619603A2 (fr)
CA (1) CA2631813A1 (fr)
IL (1) IL191988A0 (fr)
TW (1) TW200730508A (fr)
WO (1) WO2007068552A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1921070A1 (fr) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
EP1956010A1 (fr) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Hétérocycles bicycliques, médicament contenant cette composition, son utilisation et son procédé de fabrication
WO2008095847A1 (fr) * 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Hétérocycles bicycliques, agents pharmaceutiques contenant ces composés, leur utilisation et leur procédé de préparation
WO2009098061A1 (fr) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Hétérocycles spirocycliques, médicaments contenant ces composés, leur utilisation et procédé pour les produire
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
US8629153B2 (en) 2008-09-03 2014-01-14 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
US20120046284A1 (en) * 2010-02-15 2012-02-23 Boehringer Ingelheim International Gmbh Salts and hydrates of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4--cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof
CN102532107B (zh) * 2010-12-20 2014-03-12 天津药物研究院 4-取代苯胺基-7-取代烷氧高哌嗪基-喹唑啉衍生物及其制备方法和用途
EA023573B1 (ru) 2011-02-01 2016-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Дималеат 9-[4-(3-хлор-2-фторфениламино)-7-метоксихиназолин-6-илокси]-1,4-диазаспиро[5.5]ундекан-5-она, его применение в качестве лекарственного средства и его получение
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
JP6105631B2 (ja) 2012-02-09 2017-03-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，４−保護９−ヒドロキシ−５−オキソ−１，４−ジアザ−スピロ［５．５］ウンデカンの立体選択的合成方法
WO2014012859A1 (fr) 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Sel d'acide fumarique de la 9-[4-(3-chloro-2-fluoro-phénylamino)-7-méthoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undécan-5-one, son utilisation en tant que médicament et sa préparation
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
WO2015085654A1 (fr) * 2013-12-12 2015-06-18 天津合美医药科技有限公司 Dérivé de quinazoline
JP2020023441A (ja) * 2016-11-02 2020-02-13 国立大学法人九州大学 Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EA009300B1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
EP1660479A1 (fr) * 2003-07-29 2006-05-31 Astrazeneca AB Derivees de piperidyl-quinazoline utilises comme inhibiteurs de la tyrosine kinase
ES2279441T3 (es) * 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007068552A1 *

Also Published As

Publication number Publication date
IL191988A0 (en) 2008-12-29
JP2009518450A (ja) 2009-05-07
AR058286A1 (es) 2008-01-30
WO2007068552A1 (fr) 2007-06-21
BRPI0619603A2 (pt) 2011-10-11
TW200730508A (en) 2007-08-16
CA2631813A1 (fr) 2007-06-21
KR20080077009A (ko) 2008-08-20
US20070135463A1 (en) 2007-06-14
AU2006326157A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
WO2007068552A1 (fr) Heterocycles bicycliques, medicaments contenant ces composes, utilisation et procede de fabrication de ceux-ci
EP1345910B9 (fr) Derives de la quinazoline, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
EP1315718B1 (fr) Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
EP1492536B1 (fr) 4-(n-phenylamino)-quinazolines / quinolines en tant qu'inhibiteurs de la tyrosine kinase
EP1731511B1 (fr) Heterocycles bicycliques, medicaments contenant ces composés, leur utilisation et procédés permettant de les préparer
EP1315720B1 (fr) Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
EP1597240B1 (fr) Heterocycles bicycliques, medicaments les contenant, leur utilisation et leurs procedes de production
DE10042058A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1315717A1 (fr) Derives de quinazoline, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
EP1921070A1 (fr) heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
EP1641767A2 (fr) Heterocycles bicycliques, medicaments contenant ces composes, leur utilisation et procede pour leur production
DE10217689A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
EP2118075A1 (fr) Hétérocycles bicycliques, agents pharmaceutiques contenant ces composés, leur utilisation et leur procédé de préparation
EP2298305A1 (fr) 4-(N-Phenylamino)-quinazolines/quinoline en tant qu'inhibiteurs de tyrosine kinases
EP1322645A2 (fr) Quinazolines, medicaments a effet inhibant la tyrosine-kinase et contenant lesdits composes, leur utilisation et procedes permettant de les produire
WO2007101782A1 (fr) Heterocycles bicycliques, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
EP1956010A1 (fr) Hétérocycles bicycliques, médicament contenant cette composition, son utilisation et son procédé de fabrication

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20100216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100601